SCHEMBL1939979

SCHEMBL1939979

COc1ccc(C(=O)c2cn(C(C)C)c3ncnc(N)c23)cc1NC(=O)Nc1ccc(C)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.62
TEK Q02763 5/20 0.59
EGFR P00533 4/20 0.59
ERBB2 P04626 4/20 0.59
ERBB3 P21860 4/20 0.59
ERBB4 Q15303 4/20 0.59
NTRK1 P04629 4/20 0.54
NTRK2 Q16620 3/20 0.54
NTRK3 Q16288 2/20 0.54
RET P07949 3/20 0.52
KCNH2 Q12809 3/20 0.47
LCK P06239 2/20 0.45
SRC P12931 2/20 0.45
PDPK1 O15530 1/20 0.45
FLT3 P36888 2/20 0.45
KIT P10721 2/20 0.44
KDR P35968 2/20 0.44
MEN1 O00255 3/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1940223 0.93 PDGFRB (0.62) PDGFRBTEKEGFRERBB2ERBB3
SCHEMBL1941620 0.93 PDGFRB (0.62) PDGFRBTEKEGFRERBB2ERBB3
SCHEMBL1941202 0.93 PDGFRB (0.73) PDGFRBTEKEGFRERBB2ERBB3
SCHEMBL1942659 0.93 NTRK1 (0.62) PDGFRBTEKEGFRERBB2ERBB3
SCHEMBL1941531 0.93 PDGFRB (0.66) PDGFRBTEKEGFRERBB2ERBB3
SCHEMBL1939252 0.91 EGFR (0.65) PDGFRBTEKEGFRERBB2ERBB3
SCHEMBL1941262 0.91 PDGFRB (0.60) PDGFRBTEKEGFRERBB2ERBB3
SCHEMBL1940853 0.91 PDGFRB (0.59) PDGFRBTEKEGFRERBB2ERBB3
SCHEMBL1941196 0.90 NTRK1 (0.59) PDGFRBTEKEGFRERBB2ERBB3
SCHEMBL1941047 0.90 PDGFRB (0.58) PDGFRBTEKEGFRERBB2ERBB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578751-B1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PROD INC (US) 2011-06-15 EP claimed
US-7271262-B2 Pyrrolopyrimidine derivatives PFIZER INC (US) 2007-09-18 US claimed
EP-1578751-A1 PYRROLOPYRIMIDINE DERIVATIVES Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20050037999-A1 Pyrrolopyrimidine derivatives PFIZER INC 2005-02-17 US claimed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578751-B1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PROD INC (US) 2011-06-15 EP disclosed
US-7271262-B2 Pyrrolopyrimidine derivatives PFIZER INC (US) 2007-09-18 US disclosed
EP-1578751-A1 PYRROLOPYRIMIDINE DERIVATIVES Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20050037999-A1 Pyrrolopyrimidine derivatives PFIZER INC 2005-02-17 US disclosed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037999-A1 Pyrrolopyrimidine derivatives CCNA1, CCNT1, TP53 PDGFRB 2465/4885TEK 1536/4885EGFR 2758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.